NIH-funded study finds effect of PrEP on bone density is reversible

(NIH/National Institute of Allergy and Infectious Diseases) The slight loss in bone mineral density associated with HIV pre-exposure prophylaxis (PrEP) antiretroviral use is reversible in young adult patients who stop taking the drugs, according to findings presented by researchers today at the 23rd Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. PrEP is an HIV prevention strategy in which at-risk HIV-negative people take a daily pill of Truvada, which contains the antiretroviral drugs tenofovir and emtricitabine, to prevent them from becoming infected.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news